{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:11:03Z","timestamp":1785161463722,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T00:00:00Z","timestamp":1534118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome Senior Investigator Award","award":["101849\/Z\/13\/Z"],"award-info":[{"award-number":["101849\/Z\/13\/Z"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council UK","doi-asserted-by":"crossref","award":["G0801213"],"award-info":[{"award-number":["G0801213"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009253","name":"EASL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Miguel Servet Fellowship","award":["CP12\/03114"],"award-info":[{"award-number":["CP12\/03114"]}]},{"name":"Insituto de Salud Carlos III"},{"name":"LRF Programme"},{"DOI":"10.13039\/501100001381","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-CRP17-2017-06"],"award-info":[{"award-number":["NRF-CRP17-2017-06"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ymthe.2018.08.013","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T05:33:36Z","timestamp":1534397616000},"page":"2553-2566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver"],"prefix":"10.1016","volume":"26","author":[{"given":"Itziar","family":"Otano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Escors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsimran","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fusai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi M.D.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Y.J.","family":"Aw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navjyot","family":"Hansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.F.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-An","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Stauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pavesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala K.","family":"Maini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.08.013_bib1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T\u00a0cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.08.013_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2018.08.013_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.08.013_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2018.08.013_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.08.013_bib7","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1172\/JCI36604","article-title":"PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV","volume":"119","author":"Franceschini","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.08.013_bib9","doi-asserted-by":"crossref","first-page":"e1008354","DOI":"10.1080\/2162402X.2015.1008354","article-title":"T cell receptor-therapy in HBV-related hepatocellularcarcinoma","volume":"4","author":"Bertoletti","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2018.08.013_bib10","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2018.08.013_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.04.045","article-title":"Profile of tumor antigen-specific CD8 T\u00a0cells in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"137","author":"Gehring","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2018.08.013_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000444558","article-title":"Role of immunity in pathogenesis and treatment of hepatocellular carcinoma","volume":"34","author":"Schmidt","year":"2016","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ymthe.2018.08.013_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T\u00a0cell receptor redirected T\u00a0cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib15","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T\u00a0cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.08.013_bib16","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T\u00a0cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.08.013_bib17","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2013-04-495531","article-title":"Expression profiling of TCR-engineered T\u00a0cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes","volume":"122","author":"Abate-Daga","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.08.013_bib18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T\u00a0cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.08.013_bib19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2018.08.013_bib20","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/hep.23173","article-title":"Chronically inflamed livers up-regulate expression of inhibitory B7 family members","volume":"50","author":"Kassel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2018.08.013_bib21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1084\/jem.20162115","article-title":"IL-2high tissue-resident T\u00a0cells in the human liver: Sentinels for hepatotropic infection","volume":"214","author":"Pallett","year":"2017","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2018.08.013_bib22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ni.3775","article-title":"Tissue-resident memory features are linked to the magnitude of cytotoxic T\u00a0cell responses in human lung cancer","volume":"18","author":"Ganesan","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib23","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1128\/JVI.72.4.3161-3168.1998","article-title":"Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T\u00a0cells","volume":"72","author":"Korin","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib24","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1128\/JVI.01030-16","article-title":"Complementary effects of interleukin-15 and alpha interferon induce immunity in hepatitis B virus transgenic mice","volume":"90","author":"Di Scala","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T\u00a0cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","article-title":"Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients","volume":"26","author":"Dudley","year":"2003","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2018.08.013_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4049\/jimmunol.170.2.711","article-title":"Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses","volume":"170","author":"Bennett","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib28","doi-asserted-by":"crossref","first-page":"e89762","DOI":"10.1172\/jci.insight.89762","article-title":"A 3D microfluidic model for\u00a0preclinical evaluation of TCR-engineered T\u00a0cells against solid tumors","volume":"2","author":"Pavesi","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2018.08.013_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3389\/fimmu.2018.00416","article-title":"Characterizing the role of monocytes in T\u00a0cell cancer immunotherapy using a 3D microfluidic model","volume":"9","author":"Lee","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T\u00a0cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.2606","article-title":"T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion","volume":"14","author":"Utzschneider","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T\u00a0cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2018.08.013_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coviro.2016.01.002","article-title":"Immune-surveillance through exhausted effector T-cells","volume":"16","author":"Zehn","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib34","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus-specific T\u00a0cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation","volume":"128","author":"Rivino","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.08.013_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.immuni.2005.05.005","article-title":"Oscillating CD8(+) T\u00a0cell effector functions after antigen recognition in the liver","volume":"23","author":"Isogawa","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2018.08.013_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1084\/jem.20022235","article-title":"PD-1 inhibits antiviral immunity at the effector phase in the liver","volume":"198","author":"Iwai","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2018.08.013_bib37","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2018.08.013_bib38","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(17)30315-X","article-title":"A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients","volume":"66","author":"Gane","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib39","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.08.013_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2018.08.013_bib41","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2018.08.013_bib42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.08.013_bib43","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/mt.2015.71","article-title":"Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma","volume":"23","author":"Beane","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.08.013_bib44","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/0008-5472.CAN-15-3352","article-title":"TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors","volume":"76","author":"Menger","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.08.013_bib45","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.1512503112","article-title":"Generation of knock-in primary human T\u00a0cells using Cas9 ribonucleoproteins","volume":"112","author":"Schumann","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.08.013_bib46","doi-asserted-by":"crossref","first-page":"20070","DOI":"10.1038\/srep20070","article-title":"CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T\u00a0cells from cancer patients","volume":"6","author":"Su","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2018.08.013_bib47","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T\u00a0cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.08.013_bib48","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long terminal repeat CRISPR-CAR-coupled \u201cuniversal\u201d T\u00a0cells mediate potent anti-leukemic effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.08.013_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-4939-3625-0_19","article-title":"Redirecting T\u00a0cell specificity using T\u00a0cell receptor messenger RNA electroporation","volume":"1428","author":"Koh","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.gastro.2018.03.027","article-title":"Nonlytic lymphocytes engineered to express virus-specific T-cell receptors limit HBV infection by activating APOBEC3","volume":"155","author":"Koh","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2018.08.013_bib51","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.drudis.2016.05.006","article-title":"Microfluidic models for adoptive cell-mediated cancer immunotherapies","volume":"21","author":"Adriani","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2018.08.013_bib52","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.08.013_bib53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2018.08.013_bib54","doi-asserted-by":"crossref","first-page":"e47648","DOI":"10.1371\/journal.pone.0047648","article-title":"Upregulation of the Tim-3\/galectin-9 pathway of T\u00a0cell exhaustion in chronic hepatitis B virus infection","volume":"7","author":"Nebbia","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.08.013_bib55","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T\u00a0cells in persistent hepatitis B virus infection","volume":"53","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2018.08.013_bib56","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T\u00a0cell function by PD-1 blockade in inactive carrier patients is linked to T\u00a0cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2018.08.013_bib57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.immuni.2007.07.010","article-title":"Inflammation directs memory precursor and short-lived effector CD8(+) T\u00a0cell fates via the graded expression of T-bet transcription factor","volume":"27","author":"Joshi","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2018.08.013_bib58","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1172\/JCI93024","article-title":"Lymphocytes transiently expressing virus-specific T\u00a0cell receptors reduce hepatitis B virus infection","volume":"127","author":"Kah","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.08.013_bib59","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T\u00a0cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2018.08.013_bib60","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2007-11-122408","article-title":"Targeting dendritic cell signaling to regulate the response to immunization","volume":"111","author":"Escors","year":"2008","journal-title":"Blood"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618303903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618303903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:58:30Z","timestamp":1719403110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618303903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1525001618303903"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.08.013","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors.","name":"copyright","label":"Copyright"}]}}